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An invariant surface patch on the TRIM5alpha PRYSPRY
domain is required for retroviral restriction but dispensable for
capsid binding
Abstract
TRIM5alpha is a retrovirus restriction factor in the host cell cytoplasm that blocks infection before
provirus establishment. Restriction activity requires capsid (CA)-specific recognition by the PRYSPRY
domain of TRIM5alpha. To better understand the restriction mechanism, nine
charge-cluster-to-triple-alanine mutants in the TRIM5alpha PRYSPRY domain were assessed for
CA-specific restriction activity. Five mutants distributed along the TRIM5alpha PRYSPRY primary
sequence disrupted restriction activity against N-tropic murine leukemia virus and equine infectious
anemia virus. Modeling of the TRIM5alpha PRYSPRY domain based on the crystal structures of
PRYSPRY-19q13.4.1, GUSTAVUS, and TRIM21 identified a surface patch where disruptive mutants
clustered. All mutants in this patch retained CA-binding activity, a reticular distribution in the
cytoplasm, and steady-state protein levels comparable to those of the wild type. Residues in the essential
patch are conserved in TRIM5alpha orthologues and in closely related paralogues. The same surface
patch in the TRIM18 and TRIM20 PRYSPRY domains is the site of mutants causing Opitz syndrome
and familial Mediterranean fever. These results indicate that, in addition to CA-specific binding, the
PRYSPRY domain possesses a second function, possibly binding of a cofactor, that is essential for
retroviral restriction activity by TRIM5alpha.
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TRIM5 is a retrovirus restriction factor in the host cell cytoplasm that blocks infection before provirus
establishment. Restriction activity requires capsid (CA)-specific recognition by the PRYSPRY domain of
TRIM5. To better understand the restriction mechanism, nine charge-cluster-to-triple-alanine mutants in the
TRIM5 PRYSPRY domain were assessed for CA-specific restriction activity. Five mutants distributed along
the TRIM5 PRYSPRY primary sequence disrupted restriction activity against N-tropic murine leukemia
virus and equine infectious anemia virus. Modeling of the TRIM5 PRYSPRY domain based on the crystal
structures of PRYSPRY-19q13.4.1, GUSTAVUS, and TRIM21 identified a surface patch where disruptive
mutants clustered. All mutants in this patch retained CA-binding activity, a reticular distribution in the
cytoplasm, and steady-state protein levels comparable to those of the wild type. Residues in the essential patch
are conserved in TRIM5 orthologues and in closely related paralogues. The same surface patch in the
TRIM18 and TRIM20 PRYSPRY domains is the site of mutants causing Opitz syndrome and familial
Mediterranean fever. These results indicate that, in addition to CA-specific binding, the PRYSPRY domain
possesses a second function, possibly binding of a cofactor, that is essential for retroviral restriction activity
by TRIM5.
TRIM5 is a potent retroviral restriction factor that blocks
retroviruses after cell entry but before integration. This anti-
retroviral activity is species specific. For example, the rhesus
macaque orthologue acts potently against human immunode-
ficiency virus type 1 (HIV-1) (39), whereas TRIM5 from
African green monkeys inhibits HIV-1, as well as other retro-
viruses, such as N-tropic murine leukemia virus (N-MLV),
simian immunodeficiency virus, and equine infectious anemia
virus (EIAV) (15, 18, 24, 38, 50, 53). The human TRIM5
orthologue modestly blocks HIV-1 but efficiently inhibits N-
MLV (15, 18, 31, 50). Depletion of the TRIM5 protein in
human cells by RNA interference was shown to completely
relieve the block to N-MLV, demonstrating that TRIM5 is
required for the restriction of this retrovirus in human cells
(15, 31, 35, 50, 53). In addition, exogenous expression of hu-
man TRIM5 in permissive cells, such as Crandall feline kid-
ney (CRFK) fibroblasts or Mus dunni tail fibroblasts, imparts a
block against N-MLV as potent as the one observed in human
cells (15, 18, 31, 50, 53).
TRIM5 has three protein domains that are characteristic of
TRIM family members: RING finger, B-box, and coiled-coil
domains. The alpha isoform of TRIM5 contains an additional
C-terminal PRYSPRY (or B30.2) domain. Sequence variation
in the PRYSPRY domain accounts for the virus specificity of
TRIM5 orthologues (37, 38, 41). In some cases, single-amino-
acid changes in the PRYSPRY domain significantly alter the
specificity of restriction (21, 41, 51).
Simple biochemical assays of protein-protein interaction
have failed to detect TRIM5 binding to CA (6, 33). TRIM5
forms trimers in vitro which have been modeled to make mul-
tiple contacts with the hexameric CA lattice that constitutes
the surface of the mature virion core (17, 22). Consistent
with this model, noninfectious virus-like particles saturate
TRIM5-mediated restriction (44), but only if the particles
bear a mature core from a restriction-sensitive virus (10, 45).
Similarly, expression within target cells of gag, gag-pol, or gag
fragments failed to saturate the restriction activity (33).
MLV strains bearing an arginine at CA residue 110 (so-
called N-MLV) are highly susceptible to restriction by human
TRIM5, whereas MLV virions bearing glutamate in this po-
sition (B-tropic MLV [B-MLV]) are completely resistant to
restriction (15, 18, 31, 50). An assay was developed in which
human TRIM5 associated preferentially with the CA of re-
stricted N-MLV, compared with the CA of the unrestricted
B-MLV (33). This assay exploited the fact that retrovirion
cores can be liberated from the viral membrane envelope by
detergent (47). MLV was selected for study because, relative to
HIV-1, MLV CA seems more tightly associated with the virion
core (8, 13) and because N-MLV is the most sensitive reporter
virus for human TRIM5-mediated restriction (15, 18, 31, 50).
N-MLV association with human TRIM5 was dependent on
the PRYSPRY domain (33). Similarly, rhesus macaque
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TRIM5 associates with HIV-1 CA-like structures, and muta-
tions in the PRYSPRY domain that abolished this association
also resulted in loss of restriction activity (40). Therefore, while
the N-terminal RING domain and B box are thought to me-
diate an effector function required for restriction activity, the
PRYSPRY domain is viewed as the ligand-binding part of
the protein.
Here, we sought to map surface amino acid residues in the
PRYSPRY domain of human TRIM5 that are involved in
N-MLV CA binding. For this purpose, a panel of nine charge-
cluster-to-triple-alanine substitution mutants was generated.
To our surprise, only one of these mutants disrupted binding.
Instead, by placing our mutants on a three-dimensional model
of the human TRIM5 PRYSPRY domain, we identified an
exposed patch of residues that is required for restriction activ-
ity but dispensable for CA binding.
MATERIALS AND METHODS
Cell lines. Human embryonic kidney fibroblasts (293T cells) and CRFK fibro-
blasts were maintained in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Plasmids and mutagenesis. pMIG is a murine stem cell virus (MSCV)-based
bicistronic vector that directs the synthesis of green fluorescent protein (GFP)
under the control of the encephalomyocarditis virus internal ribosome entry site
(46). pMIP was derived from pMIG by replacing the GFP coding sequence with
that for puromycin acetyltransferase (34). pCIG3-N and pCIG3-B express gag
and pol from N-MLV and B-MLV, respectively (7). pMD.G expresses the ve-
sicular stomatitis virus glycoprotein (52). pCL-Eco is psi-minus Moloney MLV
expressed from the cytomegalovirus immediate-early promoter (25). The EIAV
gag-pol vector pONY3.1 and the GFP-packaging vector pONY8.0 have been
previously described (23). Human TRIM5 alanine substitution mutants (Table
1) were generated by two-step overlapping PCR and cloned into pMIP. Gluta-
thione S-transferase (GST) fusion proteins were expressed by replacing GFP-
myc of pEF/myc/cyto/GFP (Invitrogen) with GST coding sequence, followed by
a linker encoding the Gly-Ser-Gly-Gly-Ser-Gly-Gly-Ser-Gly nonapeptide.
Generation of TRIM5-expressing CRFK cell lines. Virus for transduction
was produced by transfection of 293T cells with 5 g pMD.G, 10 g pCL-Eco,
and 10 g of pMIP encoding the various TRIM5 mutants. Virus was harvested
2 days after transfection, filtered (0.45 m), and used to infect 5  104 CRFK
cells in a 12-well plate in the presence of 5 g/ml Polybrene. Pools of transduced
cells were selected in 7.5 g/ml puromycin.
Single-cycle infectivity assay. N- and B-tropic GFP reporter viruses were
produced by calcium phosphate transfection of 293T cells with 10 g pCIG3-N
or pCIG3-B, 10 g pRetroQ-GFP (Clontech), and 5 g pMD.G. EIAV reporter
viruses were generated using 10 g pONY3.1, 10 g pONY8.0, and 5 g pMD.G.
Reporter virus stocks were harvested 2 days after transfection, filtered (0.45-m
pore size), and stored at 80°C. CRFK cells (5  104 per well) were seeded in
24-well plates and infected with serial dilutions of N- or B-MLV–GFP reporter
virus; 48 h postinfection, the cells were trypsinized and fixed in 4% formalde-
hyde. Cells (104) from each sample were analyzed by flow cytometry to determine
the percentage of GFP-positive cells.
Western blotting. Cells were lysed in 50 mM Tris-HCl (pH 7.5), 50 mM NaCl,
0.5% Triton X-100, 0.5% NP-40, and 5% glycerol. Samples were then boiled in
4 sodium dodecyl sulfate (SDS) loading buffer, and the proteins were resolved
by SDS-polyacrylamide gel electrophoresis (PAGE). After transfer to a polyvi-
nylidene difluoride membrane, the blots were probed with goat anti-FLAG
epitope tag (horseradish peroxidase conjugated; Bethyl Laboratories), goat anti-
MLV CA (a gift from S. P. Goff), rabbit anti-GST (Chemicon), or mouse
anti--actin (Sigma).
CA-binding assay. 293T cells were transfected with GST-TRIM5 expression
plasmids (one 10-cm plate per sample) and trypsinized 48 h posttransfection.
Cells were harvested, washed in ice-cold phosphate-buffered saline (PBS), and
incubated for 30 min in 1 ml of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 50
mM NaCl, 0.5% Triton X-100, 0.5% NP-40, and 5% glycerol, supplemented with
Roche Complete Protease Inhibitor Cocktail tablets). Cell debris was removed
by centrifugation, and the cleared lysate was added to 20 l glutathione-Sepha-
rose beads (G beads). Ten milliliters of N- or B-MLV reporter virus was con-
centrated by ultracentrifugation through a 25% sucrose cushion at 100,000  g
for 2 h at 4°C. The virus pellets were resuspended in 100 l PBS and added to
the G beads with TRIM5-containing lysate. Samples were agitated at 4°C for
2 h and washed four times in lysis buffer. The G beads were resuspended in 10
l 4 loading buffer and boiled for 8 min, and the proteins were resolved by
SDS-PAGE. Western blotting was performed to detect MLV CA (p30) and
GST-TRIM5.
Capsid stability assay. Ten milliliters of N- or B-MLV reporter virus was
filtered and concentrated by ultracentrifugation through a 25% sucrose cushion
at 100,000  g for 2 h at 4°C. The virus pellets were resuspended in 100 l PBS
and normalized by exogenous reverse transcriptase assay. As a control, 50 l of
each virus preparation was boiled in 10% SDS for 5 min. 293T cells were
trypsinized, washed in ice-cold PBS, and lysed for 30 min in 1 ml of ice-cold lysis
buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5% Triton X-100, 0.5% NP-40,
5% glycerol, and protease inhibitors). Cell debris was removed by centrifugation,
and the cleared cell lysate (1 ml) was added to 50 l of concentrated virus (N or
B tropic) and to the 50 l of denatured viruses. Samples were accelerated onto
a 45% or 55% sucrose cushion at 100,000  g for 2 h at 4°C. One hundred
microliters from the upper fraction was harvested, and the pellet was resus-
pended in 100 l of ice-cold PBS. Samples were resolved by SDS-PAGE and
probed in Western blots with polyclonal antibody recognizing MLV CA.
Immunofluorescence microscopy. CRFK cells transduced to express FLAG-
tagged human TRIM5, the wild type or various mutants, were grown on glass
coverslips. The cells were fixed at 25°C for 10 min with 3.7% formaldehyde in
PBS and permeabilized on ice for 2 min with 2% Triton X-100 in 0.1% sodium
citrate. After being quenched with 0.1 M glycine in PBS at 25°C for 10 min, the
cells were blocked for 30 min at 25°C with 10% goat serum and 0.1% Tween 20
in PBS before being incubated overnight with anti-FLAG monoclonal antibody
(Sigma). The cells were then incubated with Alexa Fluor 488–anti-mouse sec-
ondary antibody and mounted in Vectashield with DAPI (4,6-diamidino-2-
phenylindole) (Vector laboratories). The cells were visualized with a 63 1.4-
numerical-aperture Leica HCX Planapochromat oil immersion objective using
an inverted Leica DMI 6000 CS microscope fitted with a TCS SP5 laser scanning
confocal system. Image analysis was performed using MetaMorph software pro-
vided by Universal Imaging Corp.
Structural alignment of PRYSPRY-19q13.4.1, GUSTAVUS, and TRIM21. The
crystal structures of the PRYSPRY domain from PRYSPRY-19q13.4.1 (Protein
Data Bank [PDB] entry 2FBE; residue range, 11 to 184 of chain A) (14),
GUSTAVUS (PDB entry 2FNJ; residue range, 35 to 83 and 88 to 233 of chain
A) (49), and TRIM21 (PDB entry 2IWG; residue range, 2 to 182 of chain B) (16)
were superimposed and aligned with StruPro (19) using an alpha carbon cutoff
distance of 3.5 Å. The sequence of human TRIM5 was then combined with the
structural alignment of PRYSPRY-19q13.4.1, GUSTAVUS, and TRIM21 using
ClustalX (42). To localize insertions and deletions, generally in loop regions, the
alignment was compared with a ClustalW (43) sequence-based multiple align-
ment of 10 characteristic psiBLAST (2) hits of all three aforementioned se-
quences. Additionally, the alignment was manually corrected, taking into account
information from a secondary-structure prediction of TRIM5 obtained with
NPS@ (9). The final alignment was then fed into the program Modeler 8 v2
(http://salilab.org/modeller), using 2FBE and 2FNJ as structural templates. One
hundred models were built using the model and loop optimization procedures of
the program. The resulting models were evaluated for stereochemical quality
TABLE 1. Properties of TRIM5 triple alanine substitution
mutant proteins
Namea
WT
amino
acids
Coding nucleotides
Activityb CAbindingcWT Mutant
WT  
263 KKP AAG AAG GCC GCG GCG GCA  
288 FRE TTT AGA GAG GCT GCA GCG  
295 RRY CGA CGC TAC GCA GCC GCC  
315 EDK GAA GAT AAG GCA GCT GCG  
358 KHY AAA CAT TAC GCA GCT GCC  
362 EVD GAG GTA GAC GCG GCA GCC  
367 KKT AAG AAA ACT GCG GCA GCT  
388 EKN GAA AAA AAT GCA GCA GCT  
480 RKC AGA AAA TGT GCA GCA GCT  
a Triple alanine substitution mutants were named for the position of the first
amino acid residue that was altered. WT, wild type.
b Restriction activity specific for N-MLV in transduced CRFK cells. ,
present; , absent.
c Binding of N-MLV CA to GST-TRIM5 fusion. , present; , absent.
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with PROCHECK (20). The best one was taken as the final model for the
PRYSPRY domain of human TRIM5. Pictures of the model were generated
with PyMol v0.98.
RESULTS
Selective pullout of restriction-sensitive CA is not explained
by differences in virion core stability. Experimental conditions
were previously identified under which CA from detergent-
stripped virions could be detected in association with TRIM5
(33). Interaction in this assay was specific for the restriction-
sensitive CA of N-MLV (compared with restriction-insensitive
B-MLV), required the human TRIM5 PRYSPRY domain,
and thus satisfied the expected parameters for retroviral re-
striction activity established in vivo. Nonetheless, the apparent
binding specificity in this in vitro assay might be explained by
differences in N-MLV and B-MLV core stabilities, as recently
reported using the fate-of-capsid assay (29).
To determine if differential binding to TRIM5 resulted
from differences in core stability, N-MLV and B-MLV virions
were detergent stripped using the protocol from the in vitro
binding experiment (33). The resulting particulate cores were
then accelerated through 45% or 55% sucrose, as described for
the fate-of-capsid assay (29). As expected in this assay, 55%
sucrose severely limited detection of pelletable virion CA pro-
tein (Fig. 1). In all cases, the controls and 45% and 55%
sucrose, the yields of N-MLV and B-MLV CA were identical
(Fig. 1). This indicates that, under the conditions of the in vitro
binding assay, N-MLV and B-MLV core stabilities are indis-
tinguishable, and differential core stability does not explain the
specific binding of N-MLV CA to human TRIM5.
Charge-cluster-to-alanine scanning mutagenesis of the
TRIM5 PRYSPRY domain. To better understand the mech-
anism of retroviral restriction, the in vitro binding assay was
exploited to map human TRIM5 PRYSPRY structural re-
quirements for N-MLV CA binding. Several TRIM5 C-ter-
minal truncation mutants of various lengths were generated,
but failure to detect synthesis of these mutants by Western
blotting precluded assessment in the CA-binding assay (data
not shown).
Charge-cluster-to-alanine scanning mutagenesis of the hu-
man TRIM5 PRYSPRY domain was attempted next. Clus-
ters of at least two charged amino acids in any window of 3
residues were replaced with 3 alanine residues (3, 4, 11, 48).
Such clusters of charged amino acids are likely to occupy po-
sitions on the surface of the protein (11), and replacement of
such residues is less likely to disrupt the overall conformation
and stability of the molecule (1, 12). The nine alanine substi-
tution mutants that were engineered in this fashion are shown
in Table 1 and Fig. 2.
Restriction activities of TRIM5 alanine substitution mu-
tants. To assess the TRIM5 mutants for the ability to inhibit
infection by N-MLV, nonrestrictive cat (CRFK) fibroblasts
were transduced with bicistronic retroviral vectors encoding
FLAG-tagged TRIM5 mutants and a puromycin resistance
cassette. Each transfected population was grown as a pool of
cells under puromycin selection, and steady-state levels of
TRIM5 proteins were assessed by Western blotting (Fig. 3).
The protein levels of the mutants were variable, though
TRIM5 protein levels have not been found to correlate with
the strength of restriction activity (34). Increase of TRIM5
protein by sodium butyrate, for example, was found not to
increase restriction activity (53).
To measure the retroviral restriction activities of the
TRIM5 alanine substitution mutants, pools of stable cat cell
lines bearing each of the mutants were established with
FIG. 1. N-MLV and B-MLV virion cores exhibit comparable sta-
bilities. N-MLV and B-MLV virions (N and B) were suspended in
binding assay buffer containing Triton X-100 and NP-40 (33) and
layered onto 45% or 55% sucrose cushions as indicated and as de-
scribed previously (29). The input (lanes 1 and 2), postacceleration
supernatant (lanes 3 to 6), and pellet (lanes 7 to 10) were processed by
SDS-PAGE and probed with anti-MLV CA antibody. Lanes 11 and 12
show pellets for N-MLV and B-MLV virions, respectively, that had
been boiled in SDS prior to centrifugation. NA, not applicable.
FIG. 2. Locations and restriction phenotypes of human TRIM5
surface-charge-to-triple-alanine PRYSPRY mutants. Amino acid res-
idues 280 to 493 constitute the PRYSPRY domain and are indicated
by a solid black line. Ring finger domain residues are highlighted in
yellow. B-box residues are highlighted in orange. Paircoil-predicted
coiled coils and their register (5) are indicated by lowercase letters.
Mutants are named for the first of the three consecutive residues that
were changed to alanine, e.g., mutant 263 is K263A/K264A/P265A.
Green mutants exhibited wild-type restriction activity. Restriction ac-
tivity was disrupted by red mutants.
FIG. 3. Steady-state protein levels for human TRIM5 mutants.
CRFK cells were transduced with an empty retroviral vector (Vec-
tor) or with retroviral vectors encoding FLAG epitope fusions to
wild-type TRIM5 (WT) or the indicated TRIM5 mutants (named
according to the convention described in the legend to Fig. 1).
Whole-cell lysates were probed in immunoblots with anti-FLAG
and anti-actin antibodies.
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MSCV-derived vectors as previously described (34). Each pool
of cells was transduced with serial dilutions of N- or B-MLV–
GFP reporter viruses, and the percentage of infected cells was
determined 2 days later. Compared to the empty-vector con-
trol, wild-type human TRIM5 restricted N-MLV 100- to
1,000-fold (Fig. 4). Relatively modest restriction of B-MLV by
wild-type TRIM5 was observed, but this virus was not
blocked by any of the mutants (Fig. 4). N-MLV restriction
activity was completely disrupted by mutants 295, 358, 362,
367, and 480 (Fig. 4A). Mutants 263, 288, 315, and 388 pos-
sessed N-MLV restriction activities like that of the wild type
(Fig. 4B), though a small defect in restriction activity for these
mutants was evident at higher multiplicities of infection.
EIAV is one of the few retroviruses other than N-MLV that
is known to be restricted by human TRIM5 (15). We exam-
ined the sensitivity of this virus to restriction by the TRIM5
mutants—295, 358, 362, 367, and 480—that were defective for
restriction of N-MLV. Each of these mutants was severely
compromised in its ability to restrict EIAV (Fig. 5).
CA binding of TRIM5 mutants. The abilities of the
TRIM5 alanine mutants to bind N-MLV CA were assessed
next, using the previously described in vitro binding assay (33).
GST-TRIM5 fusions were transiently expressed in 293T cells,
and MLV virions were added to the detergent-containing cell
lysate. The TRIM5-virus mixture was incubated with G
beads, and after association of the GST-TRIM5 fusion pro-
teins with the matrix, the pellet was probed by Western blotting
for MLV CA.
GST fusions of the TRIM5 mutants were expressed at
various levels, and each of them was assessed in the CA-
binding assay (Fig. 6). CA protein in each reaction was deter-
mined by immunoblotting of aliquots taken directly after viral
particles were added to the cell lysates but before G beads
were added to the mixture (CA input). After the binding re-
action, all proteins that remained associated with the G beads
were resolved by SDS-PAGE, followed by Western blotting.
Membranes were first probed with anti-CA antibody (CA pull-
out) and subsequently with anti-GST antibody (TRIM5).
As previously reported (33), wild-type human TRIM5 as-
sociated with the restricted N-MLV CA and much less so with
the unrestricted B-MLV CA (Fig. 6). This result was obtained
in 30 repetitions of this experiment; the amount of N-MLV CA
protein associated with wild-type TRIM5 was proportional to
the amount of GST-TRIM5 protein added to the binding
reaction, and the relative amount of N-MLV CA bound, com-
pared with the B-MLV CA bound, remained constant (data
not shown).
Binding experiments with each of the TRIM5 mutants
were repeated at least three times, always in parallel with the
wild type (Fig. 6). CA protein was never detected in association
with TRIM5 mutant 295, indicating a loss of CA-binding
activity. The expression level of TRIM5 mutant 367 was rel-
atively low, but no decrease in the efficiency of the N-MLV
pullout was evident. All of the remaining mutants pulled down
N-MLV with efficiency like that of the wild type and with
comparable specificity relative to B-MLV. Though local con-
centrations at the site of CA-TRIM5 interaction within the
FIG. 4. Restriction activities of human TRIM5 mutants. CRFK
cells stably transduced in pools with the indicated TRIM5 mutants
were infected with increasing amounts of N-MLV–GFP or B-MLV–
GFP (left to right on the x axis). The percentage of GFP-positive cells
(y axis) was determined 48 h later. TRIM5 mutants are clustered for
presentation according to whether they lost restriction activity (A) or
retained activity comparable to that of the wild type (WT) (B).
FIG. 5. EIAV restriction activities of selected human TRIM5 mu-
tants. CRFK cells stably transduced in pools with the indicated
TRIM5 mutants were infected with increasing amounts of EIAV-
GFP (left to right on the x axis). The percentage of GFP-positive cells
(y axis) was determined 48 h later. WT, wild type.
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cell are not known, it must not be forgotten that the recombi-
nant TRIM5 protein used in these in vitro binding experi-
ments was probably at levels significantly higher than those of
the endogenous protein, and this might have driven interac-
tions that would not occur in cells.
Imaging of TRIM5 mutants by immunofluorescence mi-
croscopy. Despite the existence of reasonably sensitive anti-
TRIM5 antibodies, the detection of endogenous TRIM5 by
immunofluorescence has not been reported, presumably be-
cause the protein is synthesized at very low levels. When ex-
pressed from transgenes, TRIM5 has been reported to con-
centrate in large cytoplasmic bodies (32) or to exhibit a diffuse
reticular pattern in the cytoplasm (27). The significance of the
cytoplasmic bodies is not known and could be an artifact of
overexpression. Several reports have in fact demonstrated full
retroviral restriction activity due to TRIM5 in the absence of
detectable cytoplasmic bodies (27, 28, 36).
The CRFK cell lines bearing TRIM5 mutants that lacked
N-MLV restriction activity were examined by immunofluores-
cence using a confocal microscope. In all cases, a punctate
cytoplasmic staining pattern was observed (Fig. 7). While, dis-
crete cytoplasmic bodies were more prominent with the wild
type, the mutants did not otherwise differ significantly from the
wild type in their subcellular distributions (Fig. 7).
Homology model of the human TRIM5 PRYSPRY domain.
The structures of the PRYSPRY domains from PRYSPRY-
19q13.4.1 (14), GUSTAVUS (49), and TRIM21 (16) have
been solved by X-ray crystallography. Although the PRYSPRY
domains of these three proteins show low sequence identity,
the three-dimensional structures are very similar. The fold of
these structures is a distorted -sandwich formed by two anti-
parallel -sheets. Residues within core structure -strands are
conserved among the butyrophilin and stonustoxin protein
families, as well as among the tripartite-motif protein family
that includes TRIM5. Therefore, the PRYSPRY domain of
human TRIM5 is likely to have the same fold.
Using the three crystal structures as templates (14, 16, 49),
we created a model of the human TRIM5 PRYSPRY domain
(Fig. 8). The sequence alignment of PRYSPRY-19q13.4.1,
GUSTAVUS, TRIM21, and TRIM5 used as the basis for
model building was generated with ClustalX (42) using a struc-
tural alignment of PRYSPRY-19q13.4.1, GUSTAVUS, and
TRIM21 as a starting point. To be able to localize insertions
and deletions, generally in loop regions, this alignment was
compared with a multiple-sequence alignment of 10 character-
istic psiBLAST (2) hits for each of the sequences. Finally, the
alignment was manually corrected, taking into account infor-
mation from a secondary-structure prediction of TRIM5. In
this way, a model structure that consists of 11 -strands con-
nected by long loops of variable length that form the -sand-
wich core could be derived. The extended N-terminal part
consists of two short -helices adjacent to one of the -sheets
(Fig. 8).
The triple alanine mutation positions were then mapped
onto the model of the PRYSPRY domain of human TRIM5
(Fig. 8). The model comprises eight of the nine alanine sub-
stitution mutants, because mutant 263 is located N-terminal of
the model’s starting point. Examination of the model revealed
a loop region on one side of the -sandwich as a hot spot for
mutants that disrupt restriction activity (Fig. 8). The colocal-
ization in three-dimensional space of these mutants, for exam-
ple, 367 and 480, was not obvious from the primary structure
(Fig. 8). Mutant 295, the only mutant with loss of the CA-
binding phenotype, is located on a surface away from the hot
spot, at the N terminus of the PRYSPRY domain model.
Mutant 388 had no effect on restriction activity against N-
MLV and localized to a loop region with a high degree of
sequence variability among TRIM5 orthologues (Fig. 8).
These regions play roles in restriction against different retro-
viruses (26, 30). Mutants 288 and 315 localized some distance
from this putative CA interaction site and had no influence on
the restriction activity of human TRIM5.
DISCUSSION
Previous studies utilized TRIM5 chimeras to demonstrate
that the specificity determinants for retroviral restriction are in
the PRYSPRY domain (27, 30, 51). This study investigated the
restriction activities and CA-binding abilities of alanine substi-
tution mutants in TRIM5. By replacing clusters of charged
amino acids in the C-terminal half of the TRIM5 protein with
alanine residues, it was hoped that regions on the surface of
the protein important for TRIM5 function as a restriction
factor would be disrupted. It was first determined if the mu-
tants could block N-MLV and EIAV infection when expressed
in an otherwise permissive cell line. Then, the mutants were
assessed for the ability to associate with N-MLV CA. Five of
the nine mutants (the triple alanine mutants 295, 358, 362, 367,
and 480) were defective for restriction activity, though only one
of them, 295, was defective for binding to N-MLV CA.
The locations of the mutants were determined on a model of
the TRIM5 PRYSPRY domain. According to this model, the
disruptive mutants cluster together on the surface of the mol-
ecule, suggesting that they disrupt a putative surface that is
essential for restriction activity (Fig. 8). Residues in this region
of the TRIM5 PRYSPRY domain are highly conserved
across TRIM5 orthologues and the closely related paral-
ogues, TRIM22, TRIM34, and TRIM6 (Fig. 9). The functional
significance of this region has not been described before, per-
haps because previous studies focused on regions with maximal
FIG. 6. CA-binding activities of TRIM5 mutants. GST-TRIM5 fusion proteins were synthesized in 293T cells. The cells were lysed with
Triton X-100 and NP-40, concentrated N- or B-MLV virions (N and B) were added, and the mixture was incubated with glutathione-Sepharose
beads. Proteins that remained associated with the beads were probed by Western blotting with anti-MLV CA and anti-GST antibodies. WT, wild
type. The numbers represent the mutants.
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sequence variation. The conserved surface patch is clearly dis-
tinct from the previously described variable regions (Fig. 9 and
10). CA-binding and N-MLV restriction activities were dis-
rupted by mutant 295. This finding is consistent with the cur-
rent model of restriction, in which the interaction of TRIM5
with CA is a prerequisite for antiviral activity.
In a previous study, N-MLV restriction activity was con-
ferred on rhesus monkey TRIM5 by substituting PRYSPRY
FIG. 7. TRIM5mutants defective for N-MLV restriction activity exhibit a punctate cytoplasmic distribution. Representative indirect immunofluorescence
images of CRFK cells stably expressing either the wild-type or mutant FLAG-tagged human TRIM5, as indicated, are shown. Fixed samples were stained with
anti-FLAG antibody (green) and counterstained with DAPI to visualize the nuclear DNA (blue). (a) Two-dimensional maximum projections of dual-color z
stacks containing 18 to 20 0.35-m sections. Bar, 10 m. (b) Low-power (10 objective) images showing fields of multiple cells. Bar, 100 m.
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variable loops from the human orthologue (30). In the context
of these chimeric proteins, human TRIM5 residues 335 to
340, 405, and 406 were shown to be important for activity.
Another study identified an important residue for N-MLV
restriction in New World monkeys (26). This amino acid po-
sition corresponds to residue 343 in the human TRIM5 or-
thologue, a residue that was not altered here.
The vast majority of the mutants that lost restriction activity
FIG. 8. Locations of the triple alanine mutants on a model of the human TRIM5 PRYSPRY domain. The model is based on crystal structures
for the PRYSPRY domains of PRYSPRY-19q13.4.1 (14), GUSTAVUS (49), and TRIM21 (16). Ribbon (A) and surface representation
(B) diagrams show the positions of mutants that disrupted N-MLV restriction activity (red) or caused no significant reduction in N-MLV restriction
activity (green).
FIG. 9. Amino acid sequence alignment of PRYSPRY domains from five TRIM5 (TR5) orthologues and from the human paralogues
TRIM22 (TR22) (NP_006065), TRIM34 (TR34) (NP_569073), and TRIM6 (TR6) (AAH65575). Residues within the PRYSPRY variable loops
are highlighted in orange (V1), green (V2), or blue (V3). Triple alanine mutants that disrupted N-MLV restriction activity but retained N-MLV
CA-binding activity are highlighted in red. The sequences were aligned using ClustalW (43). Ca, Cercopithecus aethiops (AAT81167); Mm, Macaca
mulatta (AAV91988); Hs, Homo sapiens (AAT48101); Ss, Saimiri sciureus (AAV91988); So, Saguinus oedipus (Q1ACD5).
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retained the ability to associate with N-MLV CA. This points
to a second function of the PRYSPRY domain and indicates
that CA-binding alone is not sufficient for TRIM5 to block
incoming viral particles. It is conceivable that there are regions
of intermolecular association involving the PRYSPRY domain
that are dispensable for CA binding but important for subse-
quent restriction activity. For example, the PRYSPRY domain
of one TRIM5 monomer might interact with RING or B-box
domains of another TRIM5 monomer.
Prior to this study, it was proposed that the PRYSPRY
domain possesses two independent binding surfaces and that it
functions as an adaptor molecule that mediates interaction
between two different proteins (49). The proposed interaction
surface A corresponds to the putative CA-binding surface of
TRIM5 and the site of several PYRIN/TRIM20 mutants that
cause familial Mediterranean fever. Interaction surface B cor-
responds to the site of other PYRIN/TRIM20 mutants that
cause familial Mediterranean fever and MID1/TRIM18 mu-
tants that cause Opitz syndrome. Interestingly, if the structural
model proposed here is correct, interaction surface B also
corresponds to a hot spot where the mutants that disrupt
TRIM5 restriction activity reported here are clustered. Taken
together with the large body of disease-causing mutations, the
data here suggest that an unknown factor associates with the
TRIM5 PRYSPRY domain at the hot spot for mutants that
disrupt restriction activity, that the binding surface for this
putative factor is independent of the surface that binds to CA,
and that this factor is essential for retroviral restriction activity.
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